|
|
| (22 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Estradiol]] |
| |authorTag={{DB}}
| |
| |genericName=Estradiol
| |
| |aOrAn=an
| |
| |drugClass=estrogen
| |
| |indicationType=treatment
| |
| |indication=moderate to severe vasomotor symptoms, symptoms of vulvar and vaginal atrophy due to menopause, hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, postmenopausal osteoporosis and prevention of postmenopausal osteoporosis
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=breast pain, upper respiratory tract infections, headaches, abdominal pain, pain, and edema
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA</span>
| |
| |blackBoxWarningBody=Estrogen-Alone Therapy:
| |
| *There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
| |
| *Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
| |
| *The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
| |
| *The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
| |
| *There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
| |
| *Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
| |
| *The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
| |
| *The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
| |
| | |
| Estrogen Plus Progestin Therapy:
| |
| | |
| *Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
| |
| *The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
| |
| *The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer
| |
| | |
| The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
| |
| |fdaLIADAdult=Climara is contraindicated in women with any of the following conditions:
| |
| | |
| *Undiagnosed abnormal genital bleeding
| |
| *Known, suspected, or history of breast cancer
| |
| *Known or suspected estrogen-dependent neoplasia
| |
| *Active DVT, PE, or a history of these conditions
| |
| *Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions
| |
| *Known anaphylactic reaction or angioedema with Climara
| |
| *Known liver impairment or disease
| |
| *Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
| |
| *Known or suspected pregnancy
| |
| |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Estradiol patch in adult patients.
| |
| |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Estradiol patch in adult patients.
| |
| |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Estradiol patch in pediatric patients.
| |
| |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Estradiol patch in pediatric patients.
| |
| |alcohol=Alcohol-Estradiol patch interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |